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Abstract
CHIP (carboxyl terminus of heat shock 70-interacting protein) has long been recognized as
an active member of the cellular protein quality control system given the ability of CHIP to
function as both a co-chaperone and ubiquitin ligase. We discovered a genetic disease, now
known as spinocerebellar autosomal recessive 16 (SCAR16), resulting from a coding muta-
tion that caused a loss of CHIP ubiquitin ligase function. The initial mutation describing
SCAR16 was a missense mutation in the ubiquitin ligase domain of CHIP (p.T246M). Using
multiple biophysical and cellular approaches, we demonstrated that T246M mutation results
in structural disorganization and misfolding of the CHIP U-box domain, promoting oligomeri-
zation, and increased proteasome-dependent turnover. CHIP-T246M has no ligase activity,
but maintains interactions with chaperones and chaperone-related functions. To establish
preclinical models of SCAR16, we engineered T246M at the endogenous locus in both
mice and rats. Animals homozygous for T246M had both cognitive and motor cerebellar
dysfunction distinct from those observed in the CHIP null animal model, as well as deficits in
learning and memory, reflective of the cognitive deficits reported in SCAR16 patients. We
conclude that the T246M mutation is not equivalent to the total loss of CHIP, supporting the
concept that disease-causing CHIP mutations have different biophysical and functional
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repercussions on CHIP function that may directly correlate to the spectrum of clinical pheno-
types observed in SCAR16 patients. Our findings both further expand our basic understand-
ing of CHIP biology and provide meaningful mechanistic insight underlying the molecular
drivers of SCAR16 disease pathology, which may be used to inform the development of
novel therapeutics for this devastating disease.
Author summary
CHIP is a multi-functional protein that bridges two opposing cellular processes: protein
refolding and protein degradation. Mutations in CHIP are drivers of a debilitating and
fatal disease, called spinocerebellar ataxia autosomal recessive 16 (SCAR16). Patients with
CHIP mutations suffer from pathologies in both the brain, neuroendocrine, and muscle
systems. Why or how CHIP mutations drive disease is unclear. At this early stage in
understanding SCAR16, it is imperative to establish preclinical models to help understand
the pathophysiology and mechanism of the disease, as well as to use as a platform to
design and test therapies. In this manuscript we identified the structural, biochemical, cel-
lular, and in vivo repercussions of the first mutation described in SCAR16 patients using
two rodent models engineered with CRISPR/Cas9 editing to mimic a disease-causing
human mutation. We established a new framework to better understand diseases involv-
ing the loss of CHIP function, the spectrum of disease-causing mutations, and the affected
pathways that, in turn, will allow precision medicine approaches to treat this disease.
Introduction
Protein quality control (PCQ) involves a specialized cellular surveillance system that monitors
protein integrity, identifies unfolded or damaged proteins, and then either repairs or targets
them for degradation. CHIP is abundantly expressed in most tissues and plays a central role in
maintaining protein quality control [1]. CHIP is uniquely suited as a regulator of protein qual-
ity control due to its dual functions as both a co-chaperone protein and ubiquitin ligase
enzyme. As a co-chaperone, CHIP interacts with heat shock protein (HSP)-bound proteins to
aid in substrate stabilization and refolding [2]. Conversely, as a ubiquitin ligase CHIP ubiquiti-
nates terminally-defective proteins and prepares them for degradation by the Ubiquitin Pro-
teasome System (UPS) [3]. Since the discovery of CHIP in 1999 [1], numerous reports
detailing CHIP’s co-chaperone and ubiquitin ligase activities in both the brain and heart have
been published [4–7]. However, recent reports describing surprising new roles for CHIP have
emerged. These roles include autonomous chaperone activity [8,9], the regulation of cardiac
metabolic homeostasis via the metabolic sensor AMPK (AMP-activated protein kinase) [9],
and DNA damage repair [10]. Most recently, CHIP was implicated in the pathophysiology
associated with the disease spinocerebellar autosomal recessive 16 (SCAR16) [11,12], repre-
senting the first direct association between a CHIP polymorphism and a human disease.
SCAR16 is a form of autosomal recessive spinocerebellar ataxia that can also be accompa-
nied with hypogonadism, similar to the clinical phenotype of Gordon Holmes Syndrome
(GHS) [13]. Despite over 100 years of clinical recognition, only recently have causal mutations
for GHS been identified. These mutations include the ubiquitin ligase RNF216 and deubiquiti-
nase OTUD4 [14], which suggest that faulty ubiquitination plays an essential role in the patho-
physiology of ataxia. Using exome sequencing, we identified a mutation in STUB1 (the gene
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encoding CHIP) in two patients initially diagnosed with GHS [11]. We found that this STUB1
mutation (p.T246M) resulted in a loss in the ubiquitin ligase function of CHIP [11]. Combined
with our studies demonstrating that mice lacking the expression of CHIP display motor defi-
ciencies and some aspects of the hypogonadism observed in patients with STUB1 mutations,
our CHIP knockout mouse represented the first animal model of SCAR16 [11]. Subsequently,
numerous clinical studies identified STUB1 mutations, confirming our initial identification of
a new disease [12,15–22]. Additional studies using in vitro models suggest that CHIP muta-
tions can impart differential biochemical characteristics [23,24], although how these character-
istics relate to cellular function and diseases processes are not known.
The amino acid substitutions reported in cases of SCAR16 result in nonsense, missense,
frameshift, or splicing mutations; the majority of which are predicted to significantly alter pro-
tein function [12]. Given the clinical heterogeneity of neuroendocrine phenotypes in SCAR16
patients, specific CHIP mutations likely have varying biophysical and functional consequences
to CHIP function. In this context, an animal model with a total loss of CHIP may not ade-
quately represent the spectrum of human disease represented by SCAR16. For these reasons,
we complemented the biophysical and cellular repercussions of CHIP-T246M with two rodent
models engineered with CRISPR/Cas9 to mimic this human mutation. Additionally, we per-
formed in-depth behavioral assessments to determine the effects of T246M mutation at a
whole-animal level to establish a suitable preclinical model for SCAR16. Studying CHIP muta-
tions both in vitro and in vivo allows us to delineate the contribution of co-chaperone, ubiqui-
tin ligase, and other emerging CHIP activities to specific deficits observed in a disease-relevant
context in vivo. These results provide insights that are valuable for the development of effective
therapies for this devastating degenerative disease.
Results
Biochemical and cellular analysis of CHIP-T246M
The T246M mutation destabilizes the structure of the U-box and CHIP-T246M forms deca-
mers and dodecamers in vitro and in cells: Asymmetric homodimerization of CHIP as well as
conformational flexibility are required for CHIP ubiquitin ligase activity. Critical to both the
dimerization and conformational flexibility is the U-box domain [3,25] where T246 is located
and is a highly conserved residue across CHIP homologs [11]. Furthermore, T246 is located in
the core of a conserved beta hairpin turn that lies at the interface between the two molecules of
the CHIP dimer (Fig 1A). Modeling of the T246M amino acid substitution predicts that this
mutation would, in the absence of any structural rearrangement, result in a clash between
M246 and L275. Thus, the T246M mutation likely perturbs the hydrophobic core of the U-
box, impacting the tertiary structure of the U-box and hence disrupting the formation of func-
tional dimers, consequently reducing or abolishing CHIP’s ubiquitin ligase function towards
both chaperone and non-chaperone substrates. To test the effects of T246M substitution on
U-box structure, we performed solution NMR on purified WT and T246M CHIP U-
box domains. Whereas WT CHIP U-box exhibit distinct peaks spread throughout the 2D
15N-1H HSQC spectrum characteristic of a stable, structured domain (Fig 1B), the T246M
spectrum is collapsed and has broad resonances, suggesting the loss of stable globular struc-
ture, multiple conformations and aggregation (Fig 1B). Additionally, circular dichroism spec-
tra were acquired for the isolated WT and T246M CHIP U-box domains. Compared to the
secondary structure content of the WT U-box, the signal from T246M U-box was consistent
with loss or regular secondary structure and a shift to random coil conformation (Fig 1C). Fur-
ther, we monitored the protein melting temperature (Tm) at 222 nm, the characteristic wave-
length for α-helices. The WT U-box exhibited a sigmoidal curve consistent with unfolding of a
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Fig 1. CHIP-T246M disrupts the structure of the U-box and promotes the formation of soluble oligomers. (A) The
structure of the U-box β-hairpin harboring residue 246 is shown for CHIP-WT (purple) and a Rosetta-relaxed model of
CHIP-T246M (orange). The left panels show the CHIP-WT and CHIP-T246M backbones and the side chain of T246.
The middle panels show the CHIP-T246M model. The right panels show T246M and the clashes (red discs) that would
occur without adjustment of the U-box backbone structure. The lower panels shows identical structures rotated 90˚
about the x-axis from the view in the upper panels. Hydrogen bonds between residue 246 and neighboring residues are
shown as black dashed lines for the left and middle panels. (B) 600-MHz 15N-1H transverse relaxation-optimized
spectroscopy-HSQC spectra collected at 293 K for 2H,15N-labeled WT (left) and T246M (right) CHIP U box (218–303).
(C, upper) Circular dichroism spectroscopy data collected for the U-box of WT (purple) and T246M (orange). (C, lower)
Melting point determinations for the U-box of WT and T246M CHIP at 222nm. (D) Size distribution of full-length
proteins of either WT (purple), T246M (orange), K30A (blue) and H260Q (green) CHIP determined by size-exclusion
chromatography and multi-angle lights scattering. The molecular mass of oligomeric species of each protein are indicated
(left Y-axis, thick lines) and the Rayleigh ratio chromatographs represent the amount of light scattering (right Y-axis, thin
lines). (E) COS-7 cells were co-transfected with the indicated vectors (CTRL = pcDNA3, WT = pcDNA3-mycCHIP,
T246M = pcDNA3-myc CHIP-T246M, K30A = pcDNA3-mycCHIP-K30A, H260Q = pcDNA3-mycCHIP-H260Q). Cells
were collected on ice and total protein collected and freshly separated by BN PAGE under native conditions or
SDS-PAGE under reducing conditions and immunoblotted with an anti-myc (CHIP). Locations of molecular weight
standards in kilodaltons (kD) are indicated. (F) COS-7 cells were co-transfected with the indicated transgenes. 24 hours
post transfection cells were fixed and immunostained for myc-CHIP expression (scale bar = 20 microns).
https://doi.org/10.1371/journal.pgen.1007664.g001
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globular, folded domain with a Tm of 30 ˚C, whereas T246M appeared to be unfolded at room
temperature and did not undergo any change with temperature (Fig 1C). Together these data
suggest the T246M mutation destabilizes the U-box domain, resulting in a loss of secondary
and tertiary structure.
Previous size exclusion chromatography (SEC) analysis suggested that full-length CHIP
harboring the T246M formed large aggregates greater than 670 kDa [23,24], however, SEC
alone cannot account for differences in protein conformation or account for protein-column
interactions [26]. Given the known dynamics of CHIP conformation in solution, we used an
analytical approach, SEC coupled with multi-angle light scattering, to determine true
molar mass and radius in solution and compared these data to the composition of native
CHIP-T246M when expressed in cells using blue native PAGE and immunoblot analysis. We
included in these analyses two synthetic and domain inactivating mutations of CHIP, K30A
and H260Q. These mutations abolish either the chaperone binding or ubiquitin ligase function
of CHIP, respectively [27]. As expected, both the WT protein and the K30A mutant were pre-
dominantly dimers, 72 kDa (Fig 1D, Table 1). However, the U-box domain mutants T246M
and H260Q were detected as higher-order oligomers, suggesting CHIP-T246M exist in cells
predominantly as 10-12mers (Fig 1D). Native gels of WT CHIP and the same point mutants
expressed in COS-7 cells also confirmed that CHIP-WT and CHIP-K30A form dimers
whereas CHIP-T246M and CHIP-H260Q form higher-order oligomers (Fig 1E). Next, we per-
formed indirect immunofluorescence to observe CHIP localization and expression patterns in
the same cell model. Not surprisingly, CHIP-WT protein is detected as diffuse staining
throughout the cytoplasm and within the nucleus, while CHIP-T246M protein appears as
punctate staining in the cytoplasm and perinuclear regions, perhaps reflective of CHIP-T246M
oligomers (Fig 1E). Taken together, these data suggest that the mutation destabilizes the U-
box domain resulting in the loss of ubiquitin ligase activity of CHIP-T246M previously
observed [11] and promotion of oligomerization.
CHIP-T246M maintains chaperone activity in vitro. The oligomerization of
CHIP-T246M observed in vitro could explain the loss of ubiquitin ligase activity we previously
observed [11], as well as alter chaperone and co-chaperone activities. CHIP can directly chap-
erone the refolding of heat-denatured luciferase and can further increase HSP-mediated
refolding of heat-denatured luciferase [8]. Moreover, CHIP increases the activity of AMP-acti-
vated kinase (AMPK) in vitro [9]. To determine if CHIP-T246M also results in a loss of chap-
erone-related activities, we tested the effect of this mutation on luciferase refolding and AMPK
activity in vitro. Despite the oligomeric state of CHIP-T246M, this mutant was able to promote
the refolding of heat denatured luciferase both in the absence and presence of the chaperones
HSP40 and HSP70 (Fig 2A), unlike the synthetic K30A mutant that cannot bind chaperones
and has decreased chaperone activity, as previously described [8]. Likewise, CHIP-T246M still
functioned as an AMPK chaperone, with a similar EC50 to that of CHIP-WT (Fig 2B), an
effect that required full-length CHIP, as U-box constructs had no effect on AMPK activity (Fig
2B).
The T246M mutation increases co-chaperone activity. When cells are exposed to heat
or when CHIP expression is increased, the co-chaperone activity of CHIP initiates the heat
shock response through the activation of heat shock factor 1 (HSF1). At the same time, heat
induces the oligomerization of CHIP both in vitro and in cells, enhancing the chaperone activ-
ity of the protein while not affecting ubiquitin ligase activity [8]. Remarkably, the oligomeriza-
tion of CHIP-WT that occurs with heat resembles the oligomerization of CHIP-T246M and–
H260Q [8]. Given T246M increased the interaction between CHIP and HSC70/HSP70 [11],
the oligomeric status of CHIP-T246M (Fig 1E), and our observation that CHIP-T246M retains
in vitro co-chaperone activity (Fig 2A), we hypothesized that CHIP-T246M would still have
Preclinical genetic models of SCAR16
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the ability to co-chaperone HSF1 in cells. To test whether CHIP’s regulation of HSF1 remains
intact with T246M, we transiently expressed CHIP constructs in COS-7 cells and measured
the nuclear translocation of HSF1 and changes in HSF1 transcriptional activity. As previously
reported [28], we observed that expression of CHIP-WT promotes the nuclear translocation of
HSF1 (Fig 3A) and stimulates HSF1 activity (Fig 3B) in cells cultured at physiological tempera-
ture. Remarkably, expression of CHIP-T246M also promoted HSF1 nuclear translocation to
the same extent as CHIP-WT (Fig 3A) and further enhanced HSF1 transcriptional activity (Fig
3B). In contrast, abolishing chaperone interactions via the K30A mutation of CHIP did not
affect HSF1 dynamics (Fig 3A and 3B), whereas the H260Q mutant increased HSF1 activity, as
previously shown [29]. The ability of T246M to affect HSF1 was dependent on a functional
TPR domain, as the effect of T246M on HSF1 activity is lost with the K30A-T246M double
mutant (Fig 3B).
Co-expression of CHIP-WT and CHIP-T246M does not alter oligomerization or locali-
zation. The recessive basis of SCAR16 suggests that the wild-type allele is sufficient to over-
come the disease-bearing mutated allele. Given the U-box is important to dimerization of
CHIP we hypothesized that CHIP-WT would not interact with CHIP-T246M. Interestingly,
using extracts from cells expressing both CHIP-WT and CHIP-T246M, these two proteins co-
immunoprecipitated each other (Fig 3C) suggesting the two forms of CHIP can interact with
each other. However, when we directly separated the lysates via BN-PAGE immunoblot
Table 1. SEC-MALS analysis of CHIP proteins. The true molecular weight (mw) in Daltons is provided along with the fractional contribution of each oligomeric species
(Xmer) of CHIP identified. With some proteins, a small amount was detected as very high molecular weight (VWMW).
Protein 2mer 4mer 6mer 10mer 20mer 50mer VHMW
WT (mw) 7.62E+04 1.43E+05 2.32E+05 4.87E+06
WT (%) 69.7% 25.2% 4.8% 0.4%
K30A (mw) 7.31E+04 1.38E+05 2.51E+05 1.86E+07
K30A (%) 80.4% 16.4% 2.6% 0.7%
T246M (mw) 4.13E+05 8.01E+05 1.99E+06
T246M (%) 91.0% 7.4% 1.6%
H260Q (mw) 8.13E+04 3.97E+05 8.29E+05
H260Q (%) 28.5% 67.8% 3.5%
https://doi.org/10.1371/journal.pgen.1007664.t001
Fig 2. CHIP-T246M has chaperone activity in cell-free assays. (A) Relative luciferase activity on heat-denatured
luciferase after one hour incubation with the indicated CHIP proteins (CTRL = no protein, IgG = immunoglobulin G),
either in the absence (left) or presence of HSP40 and HSP70, represented by dot plot and summarized by the mean ± 95%
CI, N = 4 experimental replicates: ,  correspond to p< 0.05, and 0.0001 via Tukey’s post hoc test compared to
CHIP-WT, †, †††† correspond to p< 0.05, and 0.0001 via Tukey’s post hoc test compared to IgG; ns indicates p> 0.05
compared to IgG. (B) AMPK kinase activity towards the Z’LYTE peptide substrate in the presence of increasing amounts
of the indicated recombinant CHIP proteins or IgG protein control represented by scatter plot and summarized by the
mean ± 95% CI, N = 3 experimental replicates. The half maximal effective concentration (EC50) for each protein is
included.
https://doi.org/10.1371/journal.pgen.1007664.g002
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Fig 3. Cellular characterization of CHIP-T246M revealed enhanced activation of HSF1, changes in solubility,
and increased turnover. (A) Immunoblot analysis of HSF1, CHIP, HP1α (nuclear marker) and MEK (cytosolic
marker) in cytosolic (C) and nuclear (N) fractions from COS-7 cells transiently transfected with the
indicated vectors (CTRL = pcDNA3, WT = pcDNA3-mycCHIP, T246M = pcDNA3-mycCHIP-T246M,
K30A = pcDNA3-mycCHIP-K30A) treated with or without heat shock as indicated. Densitometry of relative HSF1
protein is represented by the bar graph and 95% CI, N = 3 biological replicates; effect of heat shock: ‡ and † correspond to
p< 0.01 and 0.0001 via Sidak’s post hoc comparison test to cytosolic or nuclear HSF1 in control conditions at 37 ˚C;
Preclinical genetic models of SCAR16
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analysis, we observed only subtle differences in oligomerization patterns when CHIP-WT and
CHIP-T246M are co-expressed compared to the single protein expression conditions (Fig
3D). Given that BN-PAGE can limit antibody detection of proteins given the native condi-
tions, possibly obscuring changes in visualizing heterocomplexes, we also analyzed expression
via indirect immunofluorescence, and we observed that the localization of CHIP-WT was
unaffected by co-expression of CHIP-T246M (Fig 3E) despite extensive overlap in the localiza-
tion of CHIP expression within cells (Fig 3E). Together, these data suggest that while WT and
T246M CHIP interact in crude extracts, the localization and dimerization status of CHIP-WT
is largely unaffected by the presence of CHIP-T246M. Therefore, CHIP function likely also
remains intact in the heterozygous condition and the presence of WT CHIP does not appear
to alter the oligomerization or distribution of CHIP-T246M, consistent with the recessive
nature of this disease-causing mutation.
Change in solubility and increased proteasome-dependent turnover of CHIP-T246.
We consistently observed lower levels of soluble CHIP-T246M, CHIP-H260Q, and
CHIP-K30A/T246M protein relative to CHIP-WT when transiently transfecting equal
amounts of vector DNA (Fig 3B). We hypothesized that this decrease in soluble CHIP-T246M
expression could be due to changes in solubility and/or stability. To test for changes in solubil-
ity, we performed SDS-PAGE and immunoblot analysis of CHIP in both the soluble and insol-
uble fraction of whole cell lysates. We observed CHIP-T246M, -H260Q, and -K30A-T246M
CHIP in both the soluble and insoluble fraction; in contrast, CHIP-WT or -K30A was found
only in the soluble fraction (Fig 3F). In addition to the change in solubility, we also observed a
shorter half-life of soluble CHIP-T246M compared to CHIP-WT, an effect that that was
dependent on proteasome activity (Fig 3G). Taken together, our data suggest that the T246M
mutation results in altered cellular distribution, solubility, and stability, likely contributing to a
change in CHIP function.
Protein levels of CHIP-T246M are reduced in fibroblasts from SCAR16 patients and
mice engineered with the equivalent mutation. Prior to this report, analyses of
CHIP-T246M by others were limited to in vitro analyses or exogenous expression of CHIP in
cells that robustly express endogenous CHIP [23,24]. Thus, we utilized primary embryonic
fibroblasts (MEFs) isolated from mice engineered with the corresponding murine amino acid
substitution at the endogenous CHIP locus (T247M) [30]. Consistent with our exogenous
expression models, soluble CHIP protein levels were robustly reduced in MEFs isolated from
effect of CHIP transgene:  p< 0.05 via Dunnett’s post hoc comparison to nuclear HSF1 levels in control conditions. (B)
Bar graph of HSF1 transcription activity represented by the mean and 95% CI normalized to control vector (pcDNA)
conditions in COS-7 cells transiently transfected with increasing amount if DNA using the indicated vectors
(K30A-T246M = pcDNA3-mycCHIP-K30A-T246M, GFP = green fluorescent protein), N = 4 biological replicates,
 p< 0.0001 via Dunnet’s multiple comparison test to WT conditions. Immunoblot analysis of the myc-tag and β-
tubulin confirmed transgene expression. (C) COS-7 cells were co-transfected with the indicated vectors (transgenes,
HA-WT = pcDNA3-HA-CHIP, Myc-TM = pcDNA3-mycCHIP-T246M, WT + TM = HA-WT and Myc-TM). CHIP
protein was immunoprecipitated with Anti-HA or Anti-Myc affinity gel. The inputs and resulting precipitants (IP)
were separated by SDS-PAGE and immunoblotted with the indicated antibodies. (D) COS-7 cells were co-transfected
with the indicated transgenes and cell lysates were separated by BN-PAGE and immunoblotted with the indicated
antibodies. Locations of molecular weight standards in kilodaltons (kD) are indicated. (E) Micrographs of indirect
immunofluorescence from COS-7 expressing the indicated transgenes to detect CHIP-WT (left), CHIP-T246M (center),
or both (right). DAPI nuclear staining is also included (right panels) and the scale bar represents 20 microns. Co-
localization of HA-WT and Myc-TM is represented by scatter plot and the indicated Pearson correlation (ρ). (F)
Solubility analysis (in 1% Triton X-100, TX-100) of CHIP proteins, HSP70, and AMPKα in COS-7 cells determined by
immunoblot analysis. (G) Immunoblot analysis of CHIP expression (top) in COS-7 cells treated with 50 μg/ml
cycloheximide (CHX) for the indicated time (h) in the presence or absence of 20 μM MG132. β-tubulin. Densitometry
analysis (bottom) represented by dot plot and summarized by the mean ± 95% CI of relative levels of CHIP protein were
normalized to β-tubulin, N = 3 biological replicates, ‡, ‡‡, ‡‡‡ correspond to p< 0.05, 0.01, 0.0001 compared to starting
expression levels within each construct via Tukey’s post hoc test.
https://doi.org/10.1371/journal.pgen.1007664.g003
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different M246/M246 mouse embryos relative to either T246/T246 or T246/M246 littermates
(Fig 4A); however the cellular localization of endogenous CHIP protein did not appear to be
affected by the T246M mutation (Fig 4B). The decrease in steady-state CHIP in M246/M246
MEFs appeared to be at the post-translational level, as mRNA levels of Stub1 were equal across
all three genotypes (Fig 4C). We isolated protein extracts from patients homozygous for the
CHIP-T246M mutation, and again, we found a decrease in steady-state soluble CHIP-T246M
protein (Fig 4D). Together these data suggest that the reduction in CHIP-T246M protein is
likely a result of post-translational regulation.
High molecular weight species of endogenous CHIP-T246M in mouse tissue. The
decrease in steady-state CHIP-T246M was also observed in protein extracts prepared from
mouse cerebellum (Fig 4E). We analyzed potential differences in the migration of CHIP using
blue native PAGE from fresh tissue isolated from either T246/T246 or M246/M246 mice. In
protein extracts from wild-type mouse cerebellum and testes, we observed CHIP-reactive
bands predominantly at the same size as the recombinant CHIP-WT dimer (Fig 4E). In con-
trast, in samples from M246/M246 mouse cerebellums we did not observe any lower molecular
weight CHIP species, rather we observed a distinct CHIP-reactive band at the same size of
recombinant CHIP-T246M (Fig 4E), and a similar distinct, higher molecular weight species in
protein extracts isolated from testes (Fig 4E). These data suggest that even at reduced levels of
steady-state expression, CHIP-T246M does not appear to form dimers, moreover, the migra-
tion of CHIP-T246M is consistent with a specific oligomeric state.
Endogenous CHIP-T246M is degraded by the proteasome. Given the difference in
steady-state soluble protein levels of CHIP-T246M in primary cells from patients and our pre-
clinical models, we evaluated the turnover rate of CHIP in MEFs. Similar to exogenously
expressed CHIP proteins (Fig 3G), the turnover of soluble CHIP-T246M protein was rapid
(t1/2 = 1.2 h) compared to the stable, CHIP-WT protein (Fig 4F). In fact, CHIP-T246M protein
was undetectable after 6 hours of cycloheximide chase compared to approximately 75% of
CHIP-WT protein that remained after 6 hours (Fig 4F). To evaluate the solubility distribution
of CHIP-T246M and whether this distribution was effected by proteasome inhibition, we
treated MEFs with 20 μM MG132 or 0.05% DMSO for 4 hours. We collected soluble, insoluble
and total protein fractions from samples containing equal cell numbers and analyzed protein
levels using immunoblot analysis. Total T246M protein is dramatically reduced compared to
WT protein (Fig 4G). Secondly, the change in total protein levels is dramatically higher with
proteasome inhibition for T246M (4-fold) protein compared to WT, suggesting a robust pro-
teasome-dependent turnover of endogenous CHIP-T246M (Fig 4G).
CHIP-T246M maintains protein-protein interactions and the response to heat shock.
We previously demonstrated that exogenous CHIP-T246M immunoprecipitates more chaper-
one clients, such as HSP70 and HSC70, compared to CHIP-WT [11]. However, given the
strong decrease in steady-state CHIP-T246M protein expression seen in primary cells, it is
possible that these interactions are lost, resulting in a CHIP null phenotype. Remarkably, in
primary cells we found that CHIP-T246M maintains interactions with its chaperone substrate
AMPK (Fig 4H), as well as HSC70 (Fig 4I), at levels similar to CHIP-WT, consistent with our
observations that CHIP-T246M exhibits activity towards these proteins in vitro (Fig 2). CHIP
plays an important role in inducing the heat shock response via activation of HSP70, as such,
we exposed primary cells to heat and to determine if cells expressing CHIP-T246M still
respond to heat shock. M246/M246 cells still maintained activation of HSP70 during the
recovery period following heat shock (Fig 4J), whereas cells completely lacking CHIP expres-
sion had an attenuated response, as previously described [28]. These data demonstrate that
CHIP-T246M may retain some chaperone function, despite the increase in turnover.
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Fig 4. CHIP-T246M expressed from the endogenous locus results is regulated post-translationally resulting in
decreased steady-state protein levels, however, interactions between CHIP and known interactors are not affected.
(A) Immunoblot analysis of CHIP and β-tubulin protein in primary fibroblasts (MEFs) isolated from T246/T246 (T/T),
T246/M246 (T/M), or M246/M246 (M/M) mouse embryos (B) Maximum intensity projections of CHIP
immunofluorescence in MEFs treated with 0.05% DMSO or MG132. (C) qPCR analysis of Stub1 mRNA levels in MEFs
represented by the dot plot and summarized by the mean and 95% confidence intervals. (D) Immunoblot analysis of
CHIP and β-actin protein in fibroblasts isolated from control patients (WT) or siblings that are homozygous for
CHIP-T246M (II-1 and II-2). (E) Immunoblot analysis of CHIP under reducing SDS-PAGE (left) or blue native PAGE
(right) of varying amounts of protein extracts (μg) from cerebellum (Cbl) or testes (Ts) from mice with the indicated
genotypes. Protein loading on the reducing blot was confirmed via stain-free technology. As a reference, migration of
recombinant CHIP protein is provided (purple). The dashed boxes identify the regions used for longer exposure. (F)
Immunoblot analysis of CHIP and β-tubulin in soluble cell lysates from either T/T or M/M, fibroblasts, or fibroblasts
isolated from CHIP−/− embryos (KO) after exposure to cycloheximide (CHX) indicated in hours (h). Two exposures of
CHIP immunoblots are provided to help visualize M/M conditions. (G) Immunoblot analysis of CHIP and β-actin in
either the soluble or insoluble fraction of lysates or whole cell lysates from T/T or M/M MEFs treated with 20 μM MG132
or 0.05% DMSO control for 4 hours. (H) Immunoblot analysis of AMPKα1 and CHIP in cell lysates from T/T or M/M
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Generating in vivo models of CHIP-T246M. Given the advantages of both mouse and
rat models to study neurological disease, we developed a rat model also harboring the same
endogenous CHIP-T246M mutation. Similar to the decrease seen in fibroblasts isolated from
patients with T246M mutations, steady-state levels of CHIP-T246M expression are 40% lower
in protein extracts isolated from the cerebellums, whole brain, and testes of T246M rats (Fig
5A) and further decrease with age (Fig 5B). The effect of the T246M mutation on CHIP expres-
sion in the cerebellum at 32 weeks of age was also evident via immunohistochemical reactivity
(Fig 5C) and indirect immunofluorescence analysis (Fig 5D) in the rat model where we also
identified Purkinje cell degeneration, evidenced by decreased calbindin staining (Fig 5D and
5E). In mice, we observed a similar decrease in CHIP-T246M expression in the brain and tes-
tes (Fig 5F) as well as in the cerebellum, where CHIP-T246M further declined in aged mice
(Fig 5G). As we previously described, CHIP is robustly expressed in Purkinje cells [11], and
much like the rat model, in aged CHIPM246/M246 mice, we observed a decrease in CHIP
reactivity in Purkinje cells as well as a loss in calbindin-positive cells (Fig 5H), similar to our
CHIP null phenotype [11]. As seen in primary cells (Fig 4C) the decrease in tissue expression
of CHIP-T246M was not due to differences in levels of the mRNA that encodes CHIP (Fig 5I).
Decreased survival, body weight, and brain mass in CHIP-T246M models. We
observed an increase in mortality in M246/M246 rats (Fig 6A), similar to what was observed in
CHIP null mice [31]. We also found lower body weights across ages in M246/M246 rats (Fig
6B) and mice (Fig 6C). In addition to lower body weights, there was a selective, age-dependent
atrophy in the brain of M246/M246 mice, whereas the heart was not affected (Fig 6D).
Together, these data demonstrate that our two preclinical models of T246M recapitulate clini-
cal features of SCAR16 in patients including decreased protein expression of CHIP, neurode-
generation, as well as neuro- and gonadal-atrophy.
M246 results in progressive ataxia and alterations in gait. One measure of ataxia in
rodent models is measured by performance on a rotating rod, known as the rotarod test. In
rats, we found robust decreases in rotarod performance in M246/M246 mice at ages as young
as 12 weeks of age that persisted for the duration of the experiment (up to 64 weeks of age, Fig
7A and S1 Video). The loss in rotatrod performance was also accompanied by changes in gait
(Fig 7B–7E), and much like the effect on motor performance, the effect on gait was exacer-
bated by age with notable differences occurring at 32 weeks of age. In mice, we found that
young M246/M246 mice performed similarly to T246/T246 and T246/M246 mice during the
initial training on the rotarod (Fig 7F), however, with age, rotarod performance in M246/
M246 mice decreased starting around 30 weeks of age (Fig 7F), consistent with an age-depen-
dent effect on motor function. Remarkably, similarly aged mice that completely lack CHIP
expression (CHIP−/−) had a complete lack of learning of rotarod behavior (Fig 7G) [11], sug-
gesting that the CHIP-T246M model may differ in disease progression compared to the CHIP
null model. To explore this concept, we utilized a second metric of ataxia progression. This
MEFs either before (input) or after immunoprecipitation (IP) of the indicated protein. Control samples (C) contained a
mixture of 50% T/T and T/M and were immunoprecipitated with either rabbit IgG or goat IgG as controls for the CHIP
and AMPKα1 antibodies, respectively. (I) Immunoblot analysis of HSC70 and CHIP in cell lysates from T/T or M/M
MEFs either before (input) or after immunoprecipitation (IP) of CHIP. Control samples (C) contained a mixture of 50%
T/T and T/M and were immunoprecipitated with rabbit IgG to control for the CHIP antibody. (J) Immunoblot analysis
of HSP70 and CHIP in MEFs with the indicated genotypes that were treated without heat shock (no) or with heat shock
(HS) followed by the indicated recovery time. Densitometry of relative HSP70 protein is represented by the bar graph
and 95% CI, N = 3; , † correspond to p< 0.01 or 0.05 via Tukey’s post hoc test comparing M/M to either T/T or CHIP
−/−, respectively, at the indicated time point.
https://doi.org/10.1371/journal.pgen.1007664.g004
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Fig 5. Rodents engineered with CHIP-T246M had decreased expression of CHIP in the brain and testes, Purkinje
cell degeneration, increased mortality, and selective tissue atrophy. (A) Immunoblot analysis of CHIP and β-actin in
the cerebellum (cereb), brain, and testes of rats with either T246/T246 (T/T), T246/M246 (T/M), or M246/M246 (M/M)
genotypes at harvested at different ages. (B) Densitometry analysis of relative CHIP protein represented by dot plot and
summarized by the mean ± 95% CI:  p< 0.001 compared to T/T or T/M; ‡, ‡‡‡ correspond to p< 0.05, or 0.001
compared to previous time point via Tukey’s post hoc test. (C) Representative micrographs of immunohistochemical
detection of CHIP expression in rat cerebellums, 32 weeks of age, scale bar = 100 microns. (D) Indirect
immunofluorescence of either calbindin or CHIP expression and the false color overlap (co-expression) in cerebellums of
rats with the indicated genotypes, 32 weeks of age, scale bar = 100 microns. (E) Average number of Purkinje cells per
section from rats at 32 weeks of age, summarized by the mean and 95% CI, N = 3 animals per genotype. Immunoblot
analysis of CHIP in (F) brain and testes (26 weeks of age) or (G) cerebellum of mice of varying age, with the indicated
genotypes. Densitometry analysis of relative CHIP protein levels, N = 3,  p< 0.05 via t-test in comparing CHIP in M/M
mice at 52 versus 26 weeks normalized to stain-free protein levels. (H) Representative micrographs of
immunohistochemical detection of either CHIP or calbindin expression in mouse cerebellums with the indicated
genotypes, 52 weeks of age, scale bar = 200 microns. (I) qPCR analysis of Stub1 mRNA levels in four different tissues
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composite test is comprised of hind limb clasping, ledge test, gait, and kyphosis [32] and was
used to measured ataxia onset and progression in both the CHIP-T246M and CHIP−/−mouse
lines (Fig 7H). Remarkably, we found that CHIP−/− mice were already ataxic at weaning
(score = 4.4, S2 Video), and the rate of ataxia progression was equivalent to wild-type mice
(rate = 0.16 vs. 0.20 points/week in −/− vs. +/+ mice, respectively). In contrast, M246/M246
mice had a high rate of disease progression, 0.38 point/week (S3 Video), suggesting the T246M
mouse may reflect a more suitable preclinical model for SCAR16 compared to the CHIP
−/− mouse. Thus both the mouse and the rat model of CHIP-T246M demonstrate progressive
ataxia that worsens with age and recapitulates the clinical phenotype observed in SCAR16
patients that suffer from an early adult-onset progressive ataxia [12].
Behavioral repercussions of CHIP-T246M include loss of prepulse inhibition, hyperac-
tivity, and cognitive dysfunction. We utilized our rodent models to determine effects of the
T246M mutation on the additional clinical hallmarks of SCAR16—decreased sensorimotor
reflexes and cognitive dysfunction. Given the onset of ataxia phenotype in both the mouse and
rat models were observed around 30 weeks of age (Fig 7A and 7F), we tested mice at ages both
before and after this time point, 8–12 and 33 weeks, respectively. Using the acoustic startle and
prepulse inhibition test, we found that M246 had no effect on the amplitude of the acoustic
startle response in either young or adult mice (Fig 8A) suggesting a lack of an overt motoric
defect. Similarly, all young mice had comparable levels of prepulse inhibition (Fig 8B); how-
ever, older M246/M246 mice exhibited robust decreases in prepulse inhibition, indicating the
emergence of sensorimotor gating deficits by the 33 weeks of age (Fig 8B). These degenerative
deficits in prepulse inhibition are consistent with other mouse models of cerebellar degenera-
tion with profound Purkinje cell loss [33]. Interestingly, CHIP−/− mice had a profound defect
in startle amplitude (Fig 8A) and reaction time (S1 Fig), consistent with the strong motoric
defect we observed (Fig 7G); however, CHIP−/− mice, unlike M246/M246 mice, did not
exhibit any prepulse inhibition (Fig 8B).
Mice were tested in the elevated plus maze (EPM) at eight weeks of age and there was no
difference between genotypes in any of the parameters measured (Table 2). The effect of
T246M on the activity in the EPM was similar to CHIP−/− mice, in which we did not observe
increased levels of activity (Table 2); however, CHIP−/− mice spent more time in the open
arms, consistent with an aberrant pattern of exploration (Table 2). The EPM is usually given as
the first behavioral test to avoid the possible effects of extensive handling, therefore, we used
the open field test to observe any age-dependent changes in activity and impulsivity. The
M246/M246 mice traveled father (Fig 8C) and spent more time in the center of the field (Fig
8D) compared to control mice or when the mice were younger. Interestingly, a different pat-
tern emerged for rearing movements, a measure of vertical activity, as the M246/M246 mice
had reduced levels of rearing at the beginning of each session (Fig 8E), indicating a deficit in
the initial exploration of the open field, however, in older mice, higher levels of rearing
emerged in the mutant group in the last half of the session, consistent with a hyperactive phe-
notype (Fig 8E). In a similar open field test, CHIP−/− mice trended towards increased activity
(Table 2) [11], although not to the same extent as M246/M246 mice.
Additional testing in the 3-chamber choice test found that the M246/M246 genotype associ-
ated with altered social behavior (Fig 8F–8I), such that M246/M246 mice had increased prefer-
ence for social novelty towards the newly-introduced stranger 2 (Fig 8H and 8I). Further
behavioral testing revealed the M246/M246 mice had reduced marble burying, indicating a
(heart, liver, brain, testes) isolated from mice with the indicated genotypes, N = 3 mice per tissue. Relative mRNA levels
are represented by the dot plot and summarized by the mean and 95% confidence intervals.
https://doi.org/10.1371/journal.pgen.1007664.g005
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Fig 6. Decreased mortality and weight in CHIP-T246M rodents. (A) Survival analysis of rats with the indicated
genotypes (Mantel-Cox test) with the median survival (ms) indicated in weeks (w), N = 12 animals per genotype. Total
body weight of (B) rats or (C) mice with the indicated genotypes over age represented by scatter plot and summarized by
the mean ± 95% CI. For rats, N = 10 (per genotype); for mice, N = 30, 29, and 18 for T/T, T/M, and M/M, respectively.
Tukey’s post hoc test:  p< 0.05 M/M vs. T/T; †, ††, ††† correspond to p< 0.05, 0.01, 0.001 comparing M/M to T/T and
T/M; # p< 0.05 M/M vs. T/M. (D) brain weight or (E) heart weight normalized to tibia length from mice with indicated
genotypes represented by dot plot and summarized by the mean ± 95% CI: ††† corresponds to p< 0.001 comparing M/
M to T/T and T/M.
https://doi.org/10.1371/journal.pgen.1007664.g006
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decrease in exploratory digging (Table 2); moreover, no effects of genotype were observed for
olfactory ability in a buried food test (Table 2).
Our data suggest CHIP-T246M results in impulsive and risky exploration, as observed in
mouse models for mania and impulsivity and overt hyperactivity [34,35]. Interestingly, both
impulsivity and hyperactivity have been attributed to cognitive cerebellar dysfunction in
humans [36–38]; therefore, we evaluated cognitive function using the Morris water maze and
the conditioned fear response test, in rats and mice, respectively. We observed impaired learn-
ing in both young and adult M246/M246 rats measured by a decrease in the escape latency
from the water maze (Fig 9A). Moreover, young M246/M246 rats had a 42% decrease in plat-
form zone occupancy that worsened in older animals (Fig 9B), consistent with a profound def-
icit in memory recall. Likewise, M246/M246 mice had impairments in the conditioned fear
procedure, both in contextual and cue-dependent learning (Fig 9C and 9D). On the initial
training day, all genotypes had similar, low levels of freezing before any exposure to the aver-
sive foot shock. On the next day, or two weeks later, the lack of learning in M246/M246 mice
was apparent, as they did not increase their freezing time to either a contextual (Fig 9C) or
Fig 7. CHIP-T246M in rodents resulted in progressive ataxia and altered gait. Changes in (A) rotatrod performance, (B) support
base, (C) stride, and (D) support ratio over time in rats with the indicated genotypes represented by line plot and summarized by the
mean ± SEM (N = 6 animals/genotype), Tukey’s post hoc test: a, b, c, and ††† correspond to p< 0.05, 0.01, 0.001, and 0.0001
comparing M/M to T/T and T/M. (E) Graphical representation of gait parameters with foot locations indicated (RH = right hand,
RF = right foot, LH = left hand, LF = left foot). (F) Rotarod analysis during the initial learning phase (left) or over time (right)
represented by a line graph of the change in latency to fall over the first three trials, including a re-test (R) two days later,
summarized by the mean ± SEM (N = 10–20 animals/genotype), Dunnett’s post hoc test: #, ## correspond to p< 0.05, 0.01 within T/
T and T/M mice compared to trial 1; ††† p< 0.001 within all three genotypes compared to trial 1; 0.001 compared to previous time
point; Tukey’s post hoc test: ,  correspond to p< 0.05, 0.01 comparing M/M vs. T/T. (G) The initial rotarod performance in CHIP
null mice (−/−) or wild-type mice (+/+) over the first three trials, including a re-test (R) two days later, summarized by the
mean ± SEM (N = 10 animals/genotype), Tukey’s post hoc test: ‡ corresponds to p< 0.05 compare to trial 1; ,  correspond to
p< 0.05, 0.01 comparing genotypes. (H) Composite ataxia score of mice with the indicated genotypes including wild-type (+/+),
heterozygous (+/−), and homozygous (−/−) knockouts of the CHIP allele represented by scatterplot and summarized by the
mean ± SEM (N = 12 animals/genotype). Results of the linear regression analysis are depicted by the line and equation provided and
results of the mixed model analysis provided. In comparing slopes, only M/M mice had a different slope at α = 0.05.
https://doi.org/10.1371/journal.pgen.1007664.g007
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cue-dependent (Fig 9D) stimulus. This lack of response could not be attributed to hearing
impairment, since the mutant mice had normal performance in the acoustic startle test (Fig
8A). Together these data suggest significant impairment in learning and memory as a result of
CHIP-T246M and are consistent with the clinical phenotype of patients with T246M [11].
Overall, the results of the battery of behavioral assessments performed suggest that M246/
M246 leads to the dysregulation of inhibitory processes governing activity, exploration, and
sensorimotor gating, as well as impaired learning and memory in tests for conditioned fear
and cognition. Interestingly, impaired conditioned fear and decreased marble-burying were
reported in mice with deletion of maternal E3 ubiquitin ligase Ube3a, a model for Angelman
Fig 8. CHIP-T246M resulted in age-dependent deficits in sensorimotor skills, increased anxiety, and changes in sociability in
mice. (A) The amplitude of startle response (red and green are no stimulus and acoustic startle stimulus alone trials, respectively)
and (B) the amount of prepulse inhibition over increasing levels of sound, decibels (dB) in mice of the indicated genotypes. (C) The
distance traveled, (D) time spent in the center, and (E) the number of rearing movements in open field test over time. Tests (A-E)
were performed on mice with the indicated genotypes at 11–13 w of age (young) and repeated at 33 w of age (adult) and are
represented by line plot and summarized by the mean ± SEM (N = 10–20 animals/genotype), Tukey’s post hoc test: ,  correspond
to p< 0.05, 0.01 comparing M/M to T/T (or +/+ to −/−); †, ††, ††† correspond to p< 0.05, 0.01, 0.001 comparing M/M to T/T and
T/M; ‡ corresponds to p< 0.001 compared to the initial stimulus within the genotype (learning), ns = p> 0.05. (F) Time spent and
(G) number of entries in either the side with stranger 1 (S) compared to an empty cage (E). (H) Time spent and (I) number of entries
in either the side with previous stranger 1 (1) or novel stranger 2 (2). Tests F-I were performed on mice with the indicated genotypes
represented by dot plot and summarized by the mean ± 95% CI (N = 10–20 animals/genotype), Tukey’s post hoc test: ‡, ‡‡, ‡‡‡
correspond to p< 0.05, 0.01, 0.001 within genotype;  p< 0.05 M/M vs. T/T.
https://doi.org/10.1371/journal.pgen.1007664.g008
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syndrome [39], again highlighting the critical role of protein ubiquitination in cerebellar
homeostasis.
Alterations in the T246M proteome identified both known and potentially novel sub-
strates of CHIP-dependent regulation. Given the role of CHIP as a chaperone, co-chaper-
one, and ubiquitin ligase it is likely that disruption in CHIP function alters the regulation of
proteins critical to cerebellar function and protein homeostasis. To identify candidate proteins
that may mediate the pathogenesis of SCAR16, we performed unbiased proteomics via mass
spectroscopy to identify differentially expressed proteins in cerebellar lysates prepared from
either T246/T246 or M246/M246 rats at 32 weeks of age. We identified 63 and 80 unique pro-
teins that were either less or more abundant, respectively, in M246/M246 relative to T246/
T246 cerebellums (Fig 10A, S2 Fig, S1 Table). As expected, we identified a 50% decrease in
CHIP protein in M246/M246 brains as measured via MS (mean ratio = 0.5, p = 3.47E-08). We
confirmed the differential levels of selected proteins that were either increased in M246/M246
cerebellums including PDE9A and TAU, or decreased in M246/M246 cerebellums, such as
PHLPP1, SNCA, CHIP, and Pink1 (Fig 10A). We then used samples spanning multiple ages
and found that the expression levels of these proteins changes with age (Fig 10B, S3 Fig). More-
over, both the direction and magnitude of change was similar in the whole brain and cerebel-
lum, likely reflecting the important role of CHIP throughout the brain, not just in cerebellar
homeostasis. Next, we analyzed the dataset using known and predicted protein-protein associ-
ation data combined with functional enrichment analysis via the STRING database [40] to
identify proteins or pathways that may play a role in the neuro-pathophysiology of SCAR16.
Of the 143 initial proteins, 60 proteins were identified in a total of 21 protein-protein interac-
tion clusters (S2 Table) including a family of six proteins that contained CHIP and other regu-
lators of protein quality control, such as BAG3 and several F-box proteins (Fig 10C).
Additionally, we identified a cluster of proteins known to be affected by CHIP expression
including TAU (MAPT), alpha-synuclein (SNCA), and PINK1 [5,41,42]. Of note, a seven
member cluster that was also functionally enriched for coagulation processes (wound healing)
and extracellular matrix function was identified (Fig 10C), and in total, 16 proteins involved in
coagulation were affected by CHIP-T246M. Coagulation was recently identified as a significant
component of spinocerebellar ataxia disease signatures (without Friedreich ataxia) from a
Table 2. Elevated plus maze, marble burying, olfactory sensing, and open field testing in mice. The performance measurements from the elevated plus maze test, the
marble-burying assay, and buried food test for olfactory function are represented by the mean ± SEM from mice with the indicated genotypes, † p< 0.05 comparing M/M
to T/T and T/M; ‡ p< 0.05 and ¶ p = 0.07 comparing −/− and +/+.
T246/T246 T246/M246 M246/M246 CHIP+/+ CHIP−/−
Elevated plus maze
Percent open arm time 32 ± 3 30 ± 4 36 ± 4 6 ± 3 30 ± 10 ‡
Percent open arm entries 39 ± 2 41 ± 2 42 ± 3 81 ± 4 60 ± 11
Total number of entries 28 ± 2 27 ± 2 28 ± 3 21 ± 4 27 ± 6
Number of marbles buried
First test (age 12 w) 16 ± 0.6 18 ± 0.4 11 ± 1.7 †
Second test (age 32 w) 17 ± 0.4 16 ± 0.7 13 ± 1.3 †
Olfactory test
Latency to find food (s) 267 ± 74 189 ± 52 289 ± 95
Percent of group finding food 80% 95% 89%
Open field test
# of crossings, Test 1 124 ± 43 289 ± 72 ¶
# of crossings, Test 2 313 ± 39 433 ± 94
https://doi.org/10.1371/journal.pgen.1007664.t002
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Fig 9. CHIP-T246M rodents developed cognitive deficits. In rats, (A) the average latency to find the platform over
four consecutive training days in the Morris Water maze task is represented by line plot and summarized by the
mean ± SEM. (B) The amount of time spent in the target quadrant when the platform was removed after the last trial is
represented by dot plot and summarized by the mean ± 95% CI. Tests A-B were administered on rats with the
indicated genotypes at 16 w of age (young) and repeated at 36 w of age (adult), N = 6 animals/genotype, Tukey’s post
Preclinical genetic models of SCAR16
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large-scale analysis of 80,000 samples [43] and our analysis of CHIP-T246M cerebellums sup-
port the notion that coagulation may represent new targets for therapeutic interventions.
Discussion
CHIP plays a vital role in cerebellar homeostasis, however, how do the various mutations that
cause SCAR16 drive the disease pathogenesis? The simplest explanation is that the CHIP
mutations that destabilize the protein lead to an effective CHIP null condition. However, a
varying degree of CHIP protein levels is found in fibroblasts isolated from patients with CHIP
mutations. For example, the N65 mutation results in an 80% loss of CHIP protein [21],
whereas other mutations, such as T246M (Fig 4D) and the compound mutation M211I/E238
have more modest effects, approximately at the level of haploinsufficiency [16]. Moreover, the
R119/I294F and K145Q/P243K compound mutations do not appear to affect CHIP turnover
[20]. Given the recessive nature of this disease in patients [12], and the lack of phenotype
observed in our three rodent models of CHIP haploinsufficiency (Figs 6, 7, 8 and 9), these data
suggest that either the loss or change in specific activities of CHIP drive the pathophysiologies
as well as the clinical heterogeneity associated with SCAR16.
We identified that the T246M disrupts the U-box structure (Fig 1A, 1B and 1C), and the
effect of the T246M conformational change on CHIP function appears to be three-fold. First,
the destabilization of the U-box results in no appreciable ligase activity as demonstrated previ-
ously by our group [11] and others [23,24]. Secondly, CHIP-T246M is degraded in a protea-
some-dependent manner at a higher rate than CHIP-WT, both when expressed exogenously
(Fig 3G) and under native genomic conditions (Fig 4F and 4G), resulting in decreased steady-
state levels that we observed both in both T246M patients (Fig 4D) and in our rodent models
(Figs 4E, 5A, 5B, 5C, 5D, 5F, 5G and 5H). Lastly, and more surprisingly, the T246M mutation
promotes the formation of soluble oligomeric forms of CHIP, comprised of 10–12 mers in
vitro (Fig 1D and 1E) that retain chaperone activity (Fig 2). CHIP functions as a dimer [27,44],
however under heat stress, CHIP forms higher-order oligomers that appear to have increased
chaperone activity [8]. Therefore, we tested the effect of T246M on the chaperone-mediated
activation of HSF1 and found that T246M stimulates nuclear localization of HSF1 (Fig 2A)
and increased HSF1 activity (Fig 2B). We initially considered that CHIP-T246M was activating
HSF1 simply because the cells were responding to a misfolded protein insult, and not a specific
effect of CHIP-T246M on HSF1. To account for this, we engineered a CHIP-T246M protein
that also contained the K30A mutation that abolishes the interaction between CHIP and its
chaperone binding partners. Unlike T246M, the K30a-T246M double mutant had little effect
on HSF1 activity (Fig 3B) despite similar levels of insoluble CHIP protein (Fig 3F). Impor-
tantly, our data suggest that these higher-ordered oligomers of CHIP-T246M occur in vivo
and are not artifacts of over-expression (Fig 4E). Therefore, while the T246M may abolish
ligase activity, it appears that one consequence of these mutations may be altering chaperone
function by failing to process substrates usually triaged by the CHIP-HSC(P)70 complex in a
manner distinct from the CHIP null condition. We previously observed increased pulldown of
HSP70 and HSC70 with CHIP-T246M [11], and even in our rodent model with reduced
hoc test:  corresponds to p< 0.01 comparing M/M vs. T/T; †, ††, ††† correspond to p< 0.05, 0.01, 0.001 comparing
M/M to T/T and T/M; ‡ corresponds to p< 0.05 within genotype. Conditioned fear testing was measured in mice by
calculating the percentage of time freezing (no movement) during either (C) context or (D) cue-dependent learning
during the training day (D1), and over 5 minute periods either a day after training (left) or two weeks later (right).
Tests C-D are represented by line plot and summarized by the mean ± SEM (N = 10–20 animals/genotype), Tukey’s
post hoc test: †, ††, ††† correspond to p< 0.05, 0.01, 0.001 comparing M/M to T/T and T/M; ‡ corresponds to
p< 0.001 compared to the initial stimulus within the genotype (learning), ns = p> 0.05.
https://doi.org/10.1371/journal.pgen.1007664.g009
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Fig 10. Changes in the cerebellar proteome due to CHIP-T246M. (A) Heatmap (left) of cerebellar proteins determined
to be differentially expressed in M246/M246 relative to T246/T246 rats and immunoblot analysis (right) of selected
proteins in either cerebellums or whole brain in rats with the indicated genotype, GAPDH was used as a loading control.
(B) Densitometry analysis of selected proteins from either cerebellum (Cbl) or brain (Brn) from rats of the indicated
genotypes at different ages, represented by line plot and summarized by the mean ± SEM (N = 2 animals per tissue per
genotype per timepoint). 3-way ANOVA analysis identified interactions between age and genotype for all five proteins
(p< 0.0001) and no interaction between age, genotype, and tissue type (p range 0.14–0.91). Tukey’s post hoc test: , ,
 correspond to p< 0.01, 0.001, 0.0001 comparing M/M to T/T and T/M in both tissues. (C) Protein interactions
analysis identified both the interaction clusters and functional enrichment of the differentially expressed proteins
identified due to CHIP-T246M. The interaction clusters are connected with solid lines and additionally indicated by
colored protein labels. Functional enrichment analysis is labeled by the colored spheres.
https://doi.org/10.1371/journal.pgen.1007664.g010
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steady-state levels of CHIP-T246M, this interaction is maintained (Fig 4H). In fact, compara-
ble amounts of HSC70 as well as the chaperone substrate of CHIP, AMPK, immunoprecipitate
with CHIP or CHIP-T246M (Fig 4H and 4I) suggesting that even though the expression of
CHIP-T246M is reduced, it is still engaging with known client proteins at similar levels and
maintains activity towards these substrates (Fig 2). In cell culture models, the synthetic CHIP
mutation, H260Q, acted in similar to T246M regarding HSF1 activation (Fig 2B), confirming a
previous report that also identified that a U-box mutation led to changes in BAG3 protein lev-
els and suppression of the macro autophagy pathway [29]. Likewise, it was proposed that
enhancing either macro or chaperone-mediated autophagy may be beneficial in CHIPopathies
[16]. Interestingly, our proteomics analysis of the T246M rodent cerebellum revealed a
decrease in Bag3 protein levels (S2 Fig, S1 Table), so one distinct possibility for the pathology
associated with SCAR16 may be a disruption in either the macro autophagy or chaperone-
mediated autophagy pathways, rendering cells susceptible to proteinopathies. Alteration of
these autophagy pathways is implicated in other ataxias, such as spinocerebellar ataxia type 1,
3 7, and 14, [45–48]. It is important to point out that our proteomics approach does not
account for changes in cell-type distributions during neurodegeneration. Future work will
include histological analysis of these candidate proteins in the brain and cerebellum to deter-
mine the cell populations that are driving these changes.
Central to disease-based research is the establishment of preclinical models that can be used
as a platform to both better understand the mechanism of disease and to test therapies. There-
fore, we created both a mouse and rat model that genocopies the human T246M. We found
that these models recapitulate the key features of SCAR16, notably: decreased steady-state pro-
tein expression due to proteasome-dependent turnover (Figs 4E, 4F, 4G, 5A, 5B, 5F and 5G);
brain atrophy (Fig 6D); increased mortality (Fig 6A); loss of motor function (Fig 7A and 7F);
age-dependent impairment of sensorimotor function (Fig 8B); overt hyperactivity (Fig 8C, 8D
and 8E); and impaired cognitive function (Fig 9A, 9B, 9C and 9D). Given these phenotypes
were exacerbated with age, these models provide us with the ability to interrogate the patho-
physiology at difference time points in disease progression. These data further support our
previous findings that CHIP plays a critical role in cerebellar maintenance [11]. Interestingly,
some of the behavioral deficits in M246/M246 rodents overlap with those observed in CHIP
−/− mice [11], whereas others were unique to T246M mutation, further supporting our
hypothesis that disease-causing mutations in CHIP and the total loss of CHIP are not func-
tionally equivalent. For example, M246/M246 mice exhibited overt hyperactivity (Fig 8C),
risky behavior (Fig 8D), and deficits in sensory motor gaiting (Fig 8B), phenotypes not
observed in CHIP−/− mice (Table 2, Fig 8B) [11]. Conversely, CHIP−/− mice have profound
motoric defects (Fig 7G) that is apparent even at weaning (Fig 7H). Moreover, M246/M246
rodents suffer from progressive phenotypes (Figs 7H, 8B, 8C, 8D, 8E and 9A) whereas CHIP
−/− mice start with a high ataxic burden that progresses similar to healthy mice (Fig 7H). This
could be due to developmental differences in the null versus hypomorph conditions, however,
we hypothesize that the phenotypic differences observed between CHIP−/− mice and T246M
mice are likely reflective of our cell-based and in vitro findings that while T246M CHIP no lon-
ger functions as an E3 ubiquitin ligase, other CHIP functions remain intact despite this
mutation.
Perhaps even more intriguingly, the T246M mutation may modify the co-chaperone activ-
ity of CHIP in a deleterious manner. For example, mutant CHIP may be unable to either ubi-
quitinate chaperone-engaged proteins or promote the refolding of proteins that are usually
degraded by the proteasome. Similarly, mutant CHIP may promote the activation of compen-
satory pathways involved in proteins degradation or clearing protein aggregates such as autop-
hagy [29,49] that could sensitize the cells to additional proteotoxic stress. Moreover, the
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formation of soluble CHIP oligomers that alter the chaperone or co-chaperone functions of
CHIP may also contribute to the pathophysiology. Remarkably, the oligomerization of
CHIP-WT with heat is thought to increase its intrinsic chaperone activity by enhancing the
binding activity of CHIP to substrates [8], thereby providing an additional mechanism
through which coding mutations could affect CHIP activity. Alternatively, CHIP could func-
tion as a sink for other components of the ubiquitin proteasome system, such as E2 enzymes,
ultimately altering the fate of proteins that are usually modified either by CHIP or other E3
enzymes that share the same E2 enzymes. In total, our data support our previous findings that
highlight the role of aberrant ubiquitination in the pathogenesis of SCAR16; however, the loss
of CHIP ubiquitin ligase activity alone may not fully explain the molecular mechanisms under-
lying the diverse pathophysiology observed in the heterogeneity of SCAR16 disease.
CHIP mutations associated with SCAR16 occur in all three of CHIP’s functional domains,
although interestingly the majority are concentrated in the charged domain and the U-
box domain. Biochemical studies using in vitro approaches demonstrated wide variance
regarding how individual properties of CHIP change given the location of the mutation
[23,24]; clearly, more cell-based and in vivo approaches are needed to fully understand how
these mutations drive a disease that has a spectrum of clinical phenotypes. Given the diversity
of mutations and the clinical heterogeneity of the ARCA patients harboring STUB1 mutations,
we originally hypothesized that the affected protein domain might directly correlate to clinical
phenotype. For example, cognitive impairment occurred in all SCAR16 patients described in
the literature that harbor mutations in the U-box domain [11,15,17–20,22], such that residual
CHIP activity involving a defective or truncated U-box domain but intact TPR domain could
directly correlate to specific clinical symptoms in some patients. Our extensive behavioral anal-
ysis of two T246M mammalian models provides direct evidence to support this hypothesis,
demonstrating that particular cognitive deficits are in fact associated in vivo with a U-
box domain point mutation that has been demonstrated in vitro and in cells to have a partially
functionally intact TPR domain. The development of additional animal models with specific
domain mutations may help to further validate this hypothesis and identify how the multifunc-
tional roles of CHIP contribute to particular clinical pathologies. It seems clear, however, that
while defective ubiquitination contributes to SCAR16 pathology, CHIP mutation as a driver of
disease is not limited to loss of ubiquitin ligase activity but may represent a more multi-faceted
disruption of CHIP-mediated PQC.
In light of the identification of T246M CHIP mutation and subsequent designation of
SCAR16, the establishment of preclinical models of SCAR16 represents novel and important
tools to evaluate CHIP dysfunction in vivo in a disease-relevant context. Our biophysical, cellu-
lar and in vivo characterization of T246M mutation provides significant insight into both the
molecular mechanisms driving disease pathology in SCAR16 as well as basic CHIP biology, by
shedding new light on the structure-function relationship, particularly regarding the multifac-
eted activities of CHIP within the cell. Furthermore, we are hopeful these studies provide valu-
able insight required for the future development of effective therapies for this devastating
degenerative disease.
Materials and methods
Biochemical and cellular studies
Expression plasmids and recombinant proteins. Mammalian expression plasmids
pcDNA3-myc-CHIP, pcDNA3-myc-CHIP-K30A, pcDNA3-myc-CHIP-H260Q, HA-Ubiqui-
tin, FLAG-SIRT6, FLAG-HSP70, β-galactosidase, and GFP were used as described previously
[3,8,29,50,51]. CHIP, CHIP-H260Q, CHIP-K30A, CHIP-T246M and AMPK recombinant
Preclinical genetic models of SCAR16
PLOS Genetics | https://doi.org/10.1371/journal.pgen.1007664 September 17, 2018 22 / 36
proteins were produced in Escherichia coli BL21(DE3) as His-tagged fusion proteins by induc-
tion with 0.1mM isopropyl-1-thio-β-D-galactopyranoside overnight at 18˚C followed by puri-
fication with HisTrap HP columns (GE Healthcare), concentrated, and stored in in 20 mM
HEPES pH 7.4 with 150 mM NaCl.
Mutagenesis. A point mutation of threonine to methionine at position 246 of CHIP was
created for generation of single T246M point mutant and K30A-T246M double point mutant
by site-directed mutagenesis using the Q5 Site-Directed Mutagenesis Kit (New England Bio-
labs, E0554S) according to manufacturer’s instructions using previously described pcDNA3-
myc-CHIP template or pcDNA3-myc-K30A CHIP template [3] and mutagenic primers 5’-
CCGTGCATCATGCCCAGTGGC-3’ and 5’-CTCCCGCATCAGCTCAAAGC-3’ (BaseChan-
ger software, New England Biolabs). The myc-CHIP-T246M and myc-CHIP-K30A-T246M
expression plasmids were produced by transformation in Escherichia coli DH5α, purified, and
the single-base pair substitution was verified by DNA sequencing.
Light scattering. The solution molecular weights of WT CHIP, K30A, H260Q and
T246M point mutant CHIP were determined by size exclusion chromatography followed by
multi-angle light scattering (SEC-MALS) of the eluant from a size exclusion chromatography
column. The SEC-MALS system consisted of a GE Superdex 200 column connected to Wyatt
DAWN HELEOS-II multi-angle light scattering instrument and a Wyatt T-Rex refractometer
(Wyatt Technology, Santa Barbara, CA, USA). 100 μl of 0.5 mg/ml of each sample was loaded
onto the column, and the light scattering and refractive index data were collected as the eluted
samples passed through light scattering system. The molar masses of the samples eluting in
various peaks were calculated from these data using ASTRA 6 software (Wyatt Technology).
Nuclear magnetic resonance spectroscopy. Human WT and T246M U-box (amino acid
residues 212–303) recombinant proteins were expressed and purified as previously described
for WT CHIP U-box [52]. NMR spectra were recorded using a Bruker Avance 600 MHz (1H)
spectrometer at 20 ˚C in buffer containing 20 mM HEPES (pH 7.5), 50 mM NaCl, and 1 mM
DTT as previously described [52]. NMR data were processed with NMRPipe [53] and analyzed
with SPARKY (T. D. Goddard and D. G. Kneller, SPARKY 3, University of California, San
Francisco).
Circular dichroism spectroscopy. CD spectra of WT and T246M U-box CHIP were col-
lected as previously described [54] at 0.25 mg/mL and 15 ˚C in 10 mM sodium phosphate (pH
7.0) with 20 mM NaCl and 1 mM DTT. The Tm for WT and T246M U-box CHIP was deter-
mined by monitoring the temperature dependence of CD at 222 nm.
Luciferase refolding: The HSP70/HSP40 Glow-Fold Protein Refolding Kit (Boston Bio-
chem) was used per the manufactures instructions. The luciferase was heat denatured for 15
min at 42 ˚C. CHIP proteins or IgG were added to the reactions at a final concentration of
0.28 mg/ml in the absence or presence of HSP40/70 and incubated for 60 min at 30 ˚C. Activ-
ity was measured by luminescence and data normalized to heat denatured luciferase in the
absence of any additional proteins.
AMPK in vitro activity assay. Recombinant proteins CHIP, CHIP point mutants, and
AMPKα2β1γ1 in 20 mM HEPES pH 7.4 with 150 mM NaCl prepared as previously described
[9] were diluted to final concentrations of 730nM (pAMPKα2) or 7 point 5X serial dilution
curve starting from 2.8 μM in 1X kinase buffer A (50 mM HEPES pH7.5, 1 mM EGTA,0.01%
Brij-35 and 10mM MgCl2) and pre-incubated together at 30˚C for 30 min with gentle shaking.
Z’-LYTE Kinase Assay Kit-Ser/Thr 23 Peptide (Invitrogen) was utilized as per manufacturer’s
instructions to determine pAMPKα2 enzymatic activity in the presence of CHIP with each
condition measured in triplicate in 3 independent assays.
Cell culture and transfection. CHIP+/+, CHIP−/− and T246M CHIP mouse embryonic
fibroblasts (MEFs) were cultured as previously described [28]. COS-7 and shCTRL and
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shCHIP HEK293 cells were maintained in Dulbecco’s modified Eagle’s medium (Invitrogen)
supplemented with 10% fetal bovine serum (Sigma) at 37 ˚C in an atmosphere of 5% CO2. Cell
transfections were performed using X-tremeGENE 9 (Roche) with the indicated plasmid DNA
at a 1:3 DNA to X-tremeGENE 9 ratio.
mRNA analysis. CHIP mRNA levels in primary MEFs or tissue were determined using
the SingleShot SYBR Green Kit (Biorad, 1725085) and Roche LightCycler 480 with
PrimePCR SYBR green primer assays (Biorad) targeting the indicated transcripts: Actb
(qMmuCED0027505), Gapdh (qMmuCED0027497), Hprt (qMmuCED0045738), Stub1
(qMmuCED0001075), Tbp (qMmuCID0040542). Relative expression values were calculated
using the ΔCT method correcting for PCR efficiency and mean centered across the three geno-
types. Expression was normalized to the geometric mean of Actb and Hprt, the two most stable
reference mRNAs across genotypes as determined via Normfinder (also tested: Gapdh and
Tbp) [55].
Protein and mRNA isolation/analysis from mouse tissue. Intact tissues were isolated
from anesthetized 4 month-old male littermates. Tissue was stored frozen in RNAlater solu-
tion (Ambion) until protein and mRNA were isolated using the Ambion PARIS Kit (Ambion,
AM1921) as per manufacturer’s instructions. Tissue disruption prior to protein/RNA isolation
was performed with Ambion PARIS Kit Cell Disruption Buffer and Qiagen TissueLyser LT
with 5 mm steel beads. Any contaminating DNA was removed from RNA prepared by PARIS
Kit by treatment with TURBO DNA-free Kit (Ambion) and mRNA was reverse transcribed
using the iScript cDNA synthesis kit (Bio-Rad). Real-time PCR was performed using Roche
LightCycler 480 and Sso Advanced Universal SYBR Green Supermix (Biorad) with PrimePCR
SYBR green primer assays targeting the indicated mRNAs (Biorad) and methodology listed
above. Expression was normalized to the geometric mean of Actb and Gapdh, the two most sta-
ble reference mRNAs across genotypes (also tested: Hprt and Tbp).
Cell lysate collection/nuclear fractionation/isolation of total, soluble and insoluble frac-
tions. For all assays, unless otherwise noted, cell lysates were prepared by first washing cells
in cold PBS and lysed in Cell Lytic M (Sigma) containing 1X HALT protease/phosphatase
inhibitor (Pierce) and 50 μM PR619 (Lifesensors). Lysates were clarified by centrifugation at
15,000 × g for 10 min at 4 ˚C. Total protein concentration was determined by BCA protein
assay (Pierce). Alternatively, cells were lysed on ice for 15 min in Triton X-100 cell lysis buffer
(50 mM Tris, pH 7.4, 150 mM NaCl, 1% Triton X-100, 1mM EDTA, protease inhibitor (Com-
plete; Roche), 50 μM PR-619 (LifeSensors). Triton X-100 insoluble material was collected by
solubilization of the insoluble pellet following 15,000 × g centrifugation by resuspension in 2X
Laemmeli Sample buffer (Biorad), brief sonication and heating for 5 min at 100 ˚C. Nuclear
fractions were prepared using the NE-PER kit (Pierce), as per manufacturer’s instructions.
Total, soluble and insoluble fractions as shown in were prepared by first trypsinizing and
counting P2 primary MEFs grown on 15-cm tissue-culture treated dishes to near 100% con-
fluency. Cells were then divided equally between two tubes, spun at 500 × g, pellet rinsed in
PBS and spun again at 500 × g. Cells for total protein fraction (tube 1) were then lysed in 2X
Laemmeli SDS sample buffer (65mM Tris-HCl, 10% Glycerol, 2% SDS), sonicated briefly on
ice and boiled at 100 ˚C for 5 min. The cell pellet in tube 2 was then lysed for collection of solu-
ble and insoluble fractions. This pellet was lysed in Triton X-100 cell lysis buffer as described
above and soluble protein collected following centrifugation at 15,000 × g for 10 min at 4 ˚C.
The insoluble pellet was then rinsed once in lysis buffer and spun again at 15,000 × g for 10
min at 4 ˚C. The pellet was then solubilized in 2X Laemmeli SDS sample buffer (65mM Tris-
HCl, 10% Glycerol, 2% SDS), sonicated briefly on ice and boiled at 100 ˚C for 5 min. Total pro-
tein concentrations in each fraction were then determined by 660nm Protein Assay (Thermo
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Scientific) and samples of equal total protein prepared for SDS-PAGE by addition of final con-
centrations of 0.025% bromophenol blue and 100mM DTT.
Polyacrylamide gel electrophoresis, Blue native polyacrylamide gel electrophoresis, gel
immunoblotting, and densitometry. For reduced and denatured conditions, protein sam-
ples were resolved on NuPAGE Novex Bis-Tris Gels (Life Technologies) using the MOPS/LDS
buffer system or Mini-PROTEAN TGX Precast Gels (Bio-Rad) using the Tris/Glycine/SDS
buffer. Native protein samples were resolved on 4–16% NativePAGE Novex Gels (Life Tech-
nologies) using 0.001% G-250 cathode buffer. Proteins were transferred to PVDF membranes
and incubated with primary antibodies overnight (see following table for antibody informa-
tion) and detected with either anti-rabbit or anti-mouse (GE Healthcare), or anti-goat (Sigma)
HRP-conjugated antibodies and visualized with ECL Advance substrate (GE Healthcare) using
the EC3 Imaging System (UVP). For quantification of relative protein levels, densitometry
analysis was performed using LI-COR Image Studio Lite. For blue native PAGE analysis of
mouse tissues, 50 mg wet weight of tissue was homogenized for 7 min at 50 Hz using the Tis-
sueLyzer II (Qiagen) in Native PAGE sample buffer (Invitrogen) with Halt protease and phos-
phatase inhibitors (Thermo) and 1% digitonin. Lysates were cleared at 20,000 × g for 30 min at
4 ˚C. G-250 Sample Additive (Invitrogen) was added to the samples and blue native PAGE
was run using the dark blue and light blue cathode buffer protocol per the manufactures
instructions (Invitrogen). Proteins were transferred and blotted as described above.
Immunoprecipitation/co-immunoprecipitation of AMPKα1/CHIP, Hsc70/CHIP from
primary MEFs. Primary MEFs were cultured as described above and plated in 2 × 15 cm tis-
sue culture dishes and incubated overnight under normal growth conditions. 24 h after plat-
ing, cells were treated with 20 μM MG132 or DMSO for 2.5 h prior to harvest. Cells were
washed 1X in cold PBS and lysed in Cell Lytic M (Sigma) containing 1X HALT protease/phos-
phatase inhibitor (Pierce) and 50 μM PR619 (LifeSensors). Lysates were clarified by centrifuga-
tion at 15,000 × g for 10 m. Total protein concentration was determined by BCA protein assay
(Pierce) and 1.5 mg total protein clarified lysates were incubated overnight at 4 ˚C with 10 μg
of anti-AMPKα1 (R and D Systems, AF3197), anti-CHIP (Abcam, ab4447), rabbit IgG or goat
IgG antibodies. 120 μl Protein-G Dynabeads (Invitrogen) was then added to each sample and
incubated for 0.5 h at room temperature with rotation. Beads were washed four times with
Phosphate-Buffered Saline with 0.05% Tween-20; subsequently, proteins were eluted in SDS-
sample buffer and analyzed by SDS-PAGE and western blotting using anti-CHIP (Sigma,
S1073), anti-AMPKα1/2 (Cell Signaling Technologies, 2532) or anti-Hsc70 (Enzo, ADI-SPA
815) antibodies.
CHIP immunofluorescence. Micrographs were obtained as previously described [56]
with the following modifications. Cells were fixed in 4% paraformaldehyde for 10 min, then
incubated in permeabilization buffer (PBS, 0.5% Triton X-100, 1% BSA) for 10 min. Primary
and secondary antibodies were prepared at dilutions of 1:500 (CHIP-Sigma HPA043531) or
(anti-c-myc, Sigma M4439) and 1:800 (Alexa-Fluor Goat anti-rabbit or Goat anti-mouse),
respectively, in blocking buffer (PBS, 0.05% Triton X-100, 1% BSA). Coverslips were mounted
using Vectashield Hardset with Dapi (Vector Laboratories). Cells were visualized using a Zeiss
LSM 710 spectral confocal. Co-localization analysis was performed using the Coloc2 plugin (v
3.0.0) with Fiji [57,58].
HSF1 luciferase reporter assay. COS-7 cells were cultured, plated at 5000 cells/well in
clear-bottom white 96-well plates (Thermo Scientific, 165306) and transiently transfected as
described above with the indicated transgene vectors and the Qiagen Cignal Heat Shock
Response Reporter (luc) Kit (CCS4023L) as per manufacturer’s instructions. 24 h post-trans-
fection cells, were lysed and luciferase assays were performed using a Dual-Luciferase Reporter
Assay System (Promega, Madison, WI) on a BMG Labtech CLARIOstar dual-injection plate
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reader following the manufacturer’s protocol. Transfection of each construct was performed
in triplicate in each assay and a total of three assays were performed on three separate days.
Empty vector was transfected in each plate in triplicate to be used for normalization purposes.
Ratios of Renilla luciferase readings to Firefly luciferase readings were taken for each experi-
ment and triplicates were averaged. The average values of the tested constructs were normal-
ized to the activity of the empty construct.
Cycloheximide chase. COS-7 cells were co-transfected with the indicated vectors and 24
h post-transfection treated with 50 μg/ml cycloheximide for 0, 1 or 2.5 h in the presence or
absence of 20 μM proteasome inhibitor MG132 and lysates collected and separated by
SDS-PAGE and immunoblotted with antibodies against His-CHIP and β-tubulin as described
above. Primary MEFs were plated and incubated for 24 h under normal growth conditions.
Cells were then treated with for 0, 2, 4 or 6 h with 50 μg/ml cycloheximide and lysates collected
and separated by SDS-PAGE and immunoblotted with antibodies against CHIP (ab4447) and
β-tubulin as described above.
Heat shock and recovery. Two models of heat stress and recovery were utilized. For mea-
sures of heat stress/CHIP-induced nuclear translocation of HSF1 in COS-7 cells, cells were
heat shocked in a water bath for 30 min at 42 ˚C prior to lysate collection and nuclear fraction-
ation as previously described [28]. For Hsp70 induction and recovery assays in primary MEFs,
cells were heat shocked in a water bath for 10 min at 42˚C prior to recovery at 37˚C under nor-
mal growth conditions for the indicated times.
Generation of the equivalent CHIP-T246M at the endogenous rodent locus
The generation of the CHIP-T246M and CHIP−/− mice were previously described [28,30].
CRISPR/Cas9 genetic editing was used to generate the same mutation in Rattus norvegicus
(S4A Fig).
Cas9-sgRNA targeting plasmid construction. The precut pCS(puro) plasmid was used
to express human codon-optimized Cas9 and sgRNA (S4B Fig). The sgRNA were comprised
of twenty nucleotides followed by the PAM sequence: Top oligo 5’-3’:CACCGGAACCCTG
CATTACACCCAG; Bottom oligo 5’-3’ AAACCTGGGTGTAATGCAGGGTTCC. The precut
pCS(puro) plasmid was ligated with the annealed oligos DNA to generate the Cas9-sgRNA tar-
geting plasmids for STUB1 (S4B Fig).
Donor vector construction. To minimize random integrations, we used a circular donor
vector for homologous recombination repair. The targeting construct consisted of rat genomic
fragment containing exons 1–6 of Stub1 (S4C Fig). The construct carried one nucleotide sub-
stitution in the initiation codon (ATG>ACA), and two homology arms of ~2 kb each were
used as templates to repair the double-strand breaks generated by Cas9. The donor vector was
prepared using an endotoxin-free plasmid DNA kit.
Microinjection. Sprague Dawley (SD) female rats were used as embryo donors as well as
for pseudo-pregnant foster mothers. Super-ovulated SD rats (3–4 weeks of age) were mated to
SD males, and fertilized embryos were collected from the ampullae. Cas9-sgRNA targeting
plasmids and donor vector were mixed at different concentrations and co-injected into the
cytoplasm of fertilized eggs at the one-cell stage. After injection, surviving zygotes were trans-
ferred into the oviducts of SD pseudo-pregnant females.
Genotyping. Before weaning, all rats were genotyped by polymerase chain reaction (PCR)
using tail DNA using a Stub1 forward primer: 5’-CTCATGGGCAGGCTCTGGTATGG-3’;
and a Stub1 reverse primer 5’-GAGCAGTTCAGAACCCATCATCAGG-3’. PCR products
were sequenced using sanger sequencing (S4D Fig). All rats were genotyped confirmed for a
second time, post-mortem.
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Behavioral studies
Data analysis: For all procedures, measures were taken by an observer blind to animal geno-
type. Behavioral data were analyzed using two-way repeated measures Analysis of Variance
(ANOVA). If F values were< 0.05 on any individual factor or interaction of factors, Tukey’s
multiple comparison test was used to compare means.
Elevated plus maze for anxiety–like behavior. This procedure is based on a natural ten-
dency of mice to actively explore a new environment, versus their fear of being in an open
area. Mice were given one 5 min trial on the plus maze, which had two walled arms (the closed
arms, 20 cm in height) and two open arms. The maze was elevated 50 cm from the floor, and
the arms were 30 cm long. Animals were placed on the center section (8 cm × 8 cm), and
allowed to freely explore the maze. Measures were taken of time on, and the number of entries
into, the open and closed arms.
Marble-burying assay. Mice were tested in a Plexiglas cage located in a sound-attenuating
chamber with ceiling light and fan. The cage contained 5 cm of corncob bedding, with 20
black glass marbles (14 mm diameter) arranged in an equidistant 5 × 4 grid on top of the bed-
ding. Subjects were given access to the marbles for 30 min. Measures were taken of the number
of buried marbles (two-thirds of the marble covered by the bedding).
Buried food test for olfactory function. Several days before the olfactory test, an unfamil-
iar food (Froot Loops, Kellogg Co., Battle Creek, MI) was placed overnight in the home cages
of the mice. Observations of consumption were taken to ensure that the novel food was palat-
able. Sixteen to twenty hours before the test, all food was removed from the home cage. On the
day of the test, each mouse was placed in a large, clean tub cage (46 cm L × 23.5 cm W × 20 cm
H), containing paper chip bedding (3 cm deep), and allowed to explore for 5 min. The animal
was removed from the cage, and one Froot Loop was buried in the cage bedding. The animal
was then returned to the cage and given 15 min to locate the buried food. Measures were taken
of latency to find the food reward.
Open field test. Exploratory activity in a novel environment was assessed by a one-hour
trial in an open field chamber (41 cm × 41 cm × 30 cm) crossed by a grid of photobeams (Ver-
saMax system, AccuScan Instruments). Counts were taken of the number of photobeams bro-
ken during the trial in 5-min intervals, with separate measures for ambulation (total distance
traveled) and rearing movements. Time spent in the center region of the open field was mea-
sured as an index of anxiety-like behavior. Mice were tested at two ages: 8–9 weeks- and 32
weeks of age.
Rotarod. Mice and rats were tested for motor coordination and learning on an accelerat-
ing rotarod (Ugo Basile, Stoelting Co., Wood Dale, IL or Rot-Rod, Softmaze, respectively). For
mice, the first test session animals consisted of three trials, with 45 s between each trial. Two
additional trials were given 48 hours later. Rpm (revolutions per min) was set at an initial
value of three, with a progressive increase to a maximum of 30 rpm across 5 min (the maxi-
mum trial length). Measures were taken for latency to fall from the top of the rotating barrel.
Additional tests (two trials per test) were conducted at the indicated ages. For rats, each rat
was placed on the Rotarod at a constant speed (5 rpm) for a maximum of 5 min, and at an
accelerated speed (4 to 40 rpm in 5 min) for a maximum of 5 min. The latency to fall was
recorded. Rats perform four trials for each time point, with 15 min rest between trials. For
summary analysis, the mean latency to fall of each trial was used.
Sociability in a 3-chamber choice test. Mice were evaluated for differences in social pref-
erence. The test session consisted of three 10-min phases: a habituation period, a test for socia-
bility, and a test for social novelty preference. For the sociability assay, mice were given a
choice between being in the proximity of an unfamiliar conspecific (“stranger 1”), versus being
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alone. In the social novelty phase, mice were given a choice between the already-investigated
stranger 1, versus a new, unfamiliar mouse (“stranger 2”). The social testing apparatus was a
rectangular, 3-chambered box fabricated from clear Plexiglas. Dividing walls had doorways
allowing access into each chamber. An automated image tracking system (Noldus Ethovision)
provided measures of entries and duration in each side of the social test box, as well as time in
spent within 5 cm of the Plexiglas cages (the cage proximity zone).
At the start of the test, the mouse was placed in the middle chamber and allowed to explore
for 10 min, with the doorways into the two side chambers open. After the habituation period,
the mouse was enclosed in the center compartment of the social test box, and an unfamiliar,
sex-matched C57BL/6J mouse (stranger 1) was placed in one of the side chambers. The
stranger mouse was enclosed in a small Plexiglas cage drilled with holes, which allowed nose
contact, but prevented fighting. An identical empty Plexiglas cage was placed in the opposite
side of the chamber. Following placement of the stranger and the empty cage, the doors were
re-opened, and the subject was allowed to explore the entire social test box for 10 min. Mea-
sures were taken of the amount of time spent in each chamber and the number of entries into
each chamber by the automated tracking system. At the end of the sociability phase, stranger 2
was placed in the empty Plexiglas container, and the test mouse was given an additional 10
min to explore the social test box.
Acoustic startle and prepulse inhibition. This procedure was used to assess auditory
function, reactivity to environmental stimuli, and sensorimotor gating. The test was based on
the reflexive whole-body flinch, or startle response, which follows exposure to a sudden noise.
Measures were taken of startle magnitude and prepulse inhibition, which occurs when a weak
prestimulus leads to a reduced startle in response to a subsequent louder noise. Mice were
tested at two ages: 11–13 weeks and 33 weeks. For each test, mice were placed into individual
small Plexiglas cylinders within larger, sound-attenuating chambers. Each cylinder was seated
upon a piezoelectric transducer, which allowed vibrations to be quantified and displayed on a
computer. The chambers included a ceiling light, fan, and a loudspeaker for the acoustic sti-
muli. Background sound levels (70 dB) and calibration of the acoustic stimuli were confirmed
with a digital sound level meter (San Diego Instruments). Each session consisted of 42 trials
that began with a 5-min habituation period. There were seven different types of trials: the no-
stimulus trials, trials with the acoustic startle stimulus (40 msec; 120 dB) alone, and trials in
which a prepulse stimulus (20 msec; either 74, 78, 82, 86, or 90 dB) occurred 100 ms before the
onset of the startle stimulus. Measures were taken of the startle amplitude for each trial across
a 65-msec sampling window, and an overall analysis was performed for each subject’s data for
levels of prepulse inhibition at each prepulse sound level (calculated as 100—[(response ampli-
tude for prepulse stimulus and startle stimulus together / response amplitude for startle stimu-
lus alone) × 100].
Fear conditioning. Mice were evaluated for learning and memory in a conditioned fear
test, using the Near-Infrared image tracking system (MED Associates, Burlington, VT). The
procedure had the following phases: training on Day 1, a test for context-dependent learning
on Day 2, and a test for cue-dependent learning on Day 3. Follow-up tests for retention of
learning were conducted 2 weeks later.
Training. On Day 1, each mouse was placed in the test chamber, contained in a sound-
attenuating box, and allowed to explore for 2 min. The mice were then exposed to a 30 s tone
(80 dB), followed by a 2 s scrambled foot shock (0.4 mA). Mice received two additional shock-
tone pairings, with 80 s between each pairing.
Context- and cue-dependent learning. On Day 2, mice were placed back into the original
conditioning chamber for a test of contextual learning. Levels of freezing (immobility) were
determined across a 5 min session. On Day 3, mice were evaluated for associative learning to
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the auditory cue in another 5 min session. The conditioning chambers were modified using a
Plexiglas insert to change the wall and floor surface, and a novel odor (dilute vanilla flavoring)
was added to the sound-attenuating box. Mice were placed in the modified chamber and
allowed to explore. After 2 min, the acoustic stimulus (an 80 dB tone) was presented for a 3
min period. Levels of freezing before and during the stimulus were obtained by the image
tracking system. Two weeks following each test, mice were given second tests to evaluate reten-
tion of context- and cue-dependent learning.
Gait analysis. The CatWalk XT (Noldus information Technology, Wageningen, Nether-
lands) was used to analyze gait of unforced moving rats. CatWalk XT consists a hardware sys-
tem of a long glass walkway plate, illuminated with green light that is reflected within the glass
at points be touched, a high-speed video camera, and a software package for quantitative
assessment of animal footprints. The parameters we observed included stride length: the dis-
tance between successive placements of the same paw; base of support: the average width
between either the front paws or the hind paw; step cycle: the time in seconds between two
consecutive initial contact of the same paw. All rats were trained to cross the runway in consis-
tently at least six times a day for a week before any experimentation. A successful run was
defined as an animal finishing the run down the tracks without any interruption or hesitation.
Rats that failed the CatWalk training were excluded from the study. An average number of five
replicate crossings by each rat was recorded. Rats were subjected to computer-assisted Cat-
Walk monthly after 8 weeks of age.
Morris water maze. The Morris water maze task was used to assess learning and memory.
The task was conducted in a round tank, 160 cm in diameter and 54 cm deep, filled with
water. The wall was colored with non-toxic black paint to ensure opaqueness. Throughout test-
ing, the water temperature was monitored and maintained at 21 ˚C. The tank was divided into
four equally sized quadrants, and a circular acrylic escape platform was placed in one of the
quadrants. The escape platform was submerged in water by 2 cm so that it was not visible to
the animals. A camera mounted above the tank recorded the movement of the animals in each
trial. The Sunny Instruments Morris water maze Tracking Software was used to record the
latency to reach the escape platform and the time spent in the target quadrant. The water maze
task consisted of four training days with four trials on each day. In each trial, the animals were
placed in the water facing the tank wall and had to locate the escape platform. The initial posi-
tion of the animal was the vertices of one of the four quadrants and was different for each trial.
It was assigned randomly and counterbalanced for the genotypes. Animals could utilize exter-
nal visual cues on the walls surrounding the tank to locate the platform. The trial was com-
pleted when the animal either found the escape platform or 60 s had passed. If the animal was
unable to locate the platform in 60 s, it was gently led to the platform. Animals were allowed to
remain on the escape platform for 15 s before being removed and dried for the next trial. In
addition, the platform position was kept constant between trials and days. The four trials of
the first four training days were used as an indicator of spatial working memory. On day 5, the
animals performed a 60 s probe trial without the platform. During this trial, the time spent in
the target quadrant was recorded for each animal.
Study approval. All animal work was performed according to one of the following pro-
tocols: 1) the Guide for the Care and Use of Laboratory Animals under approved IACUC
animal use protocols within the AAALAC accredited program at the University of North
Carolina at Chapel Hill (Animal Welfare Assurance Number: A-3410–01); or 2) the require-
ments of the Medical Research Ethics Committee Board of the First Affiliated Hospital of
Zhengzhou University. All animals were euthanized according to the regulations of the gov-
erning protocol.
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Proteomic studies
Sample preparation, iTRAQ labeling, and LC-MS/MS analysis: Immediately after termination,
the cerebellum was dissected, briefly washed with PBS solution, snap-frozen in liquid nitrogen,
and stored at -80 ˚C until use. Frozen samples were obtained from both genotypes (N = 3) and
total proteins of each sample were extracted using lysis buffer (1% SDS, 50 mM Tris–HCl (pH
6.8), 10% glycerol, and 1× protease inhibitor). Lysates were boiled in water for 15 min, soni-
cated (80 W, pulse at 10 s then 15 s for 10 times), and then boiled again for 15 min. Finally,
lysates were centrifuged at high speed for 30 min, and supernatants collected and stored in ali-
quots at—80 ˚C (longer term).
Protein solutions (100 μg) containing 8 M urea was diluted four times with 100 mM
Triethylammonium bicarbonate. Trypsin Gold (Promega, Madison, WI, USA) was used to
digest the proteins with the ratio of protein: trypsin = 40:1 at 37 ˚C overnight. After trypsin
digestion, peptides were desalted with a Strata X C18 column (Phenomenex) and vacuum-
dried according to the manufacturer’s protocol. Samples were labeled using the iTRAQ
Reagent-8plex Multiplex Kit (AB SCIEX, Framingham, USA), according to the manufacturer’s
instructions. T246/T246 samples were labeled with iTRAQ tags 117, 118, and 119, while
M246/M246 samples were labeled with tags 114, 115, and 116 (three replicates from each
group). After 2 h of incubation at room temperature, labeled samples were mixed at equal
ratios, desalted with a Strata X C18 column (Phenomenex), and vacuum-dried according to
the manufacturer’s protocol.
The peptides were separated on a Shimadzu LC-20AB HPLC Pump system coupled with a
high pH RP column. The peptides were reconstituted with buffer A (5% acetonitrile, 95%
H2O, adjusted pH to 9.8 with ammonia) to 2 ml and loaded onto a column containing 5-μm
particles (Phenomenex). The peptides are separated at a flow rate of 1 mL/min with a gradient
of 5% buffer B (5% H2O, 95% acetonitrile, adjusted pH to 9.8 with ammonia) for 10 min,
5–35% buffer B for 40min, 35–95% buffer B for 1 min. The system was then maintained in
95% buffer B for 3 min and decreased to 5% within 1 min before equilibrating with 5% buffer
B for 10 min. Elution is monitored by measuring absorbance at 214 nm, and fractions are col-
lected every 1 min. The eluted peptides are pooled as 20 fractions and vacuum dried.
Each fraction was resuspended in buffer A (2% acetonitrile and 0.1% formic acid in water)
and centrifuged at 20,000 × g for 10 min. The supernatant was loaded onto a C18 trap column
5 μl/min for 8 min using an LC-20AD nano-HPLC instrument (Shimadzu, Kyoto, Japan) by
the autosampler. Then, the peptides were eluted from trap column and separated by an analyti-
cal C18 column (inner diameter 75 μm) packed in-house. The gradient was run at 300 nl/min
starting from 8 to 35% of buffer B (2% H2O and 0.1% formic acid in acetonitrile) in 35 min,
then going up to 60% in 5 min, then maintenance at 80% B for 5 min, and finally returned to
5% in 0.1 min and equilibrated for 10 min.
Data acquisition was performed with a TripleTOF 5600 System (SCIEX, Framingham, MA,
USA) equipped with a Nanospray III source (SCIEX, Framingham, MA, USA), a pulled quartz
tip as the emitter (New Objectives, Woburn, MA) and controlled with software Analyst 1.6 (AB
SCIEX, Concord, ON). Data were acquired with the following MS conditions: ion spray voltage
2,300 V, curtain gas of 30, nebulizer gas of 15, and interface heater temperature of 150 ˚C. High
sensitivity mode was used for the whole data acquisition. The accumulation time for MS1 is
250ms, and the mass ranges were from 350 to 1500 Da. Based on the intensity in MS1 survey, as
many as 30 product ion scans were collected exceeding a threshold of 120 counts per second
(counts/s) and with charge-state 2+ to 5+. The dynamic exclusion was set for 1/2 of peak width
(12 s). For ITRAQ data acquisition, the collision energy was adjusted to all precursor ions for
collision-induced dissociation, and the Q2 transmission window for 100Da was 100%.
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Protein identification. The raw MS/MS data were converted into MGF format by Proteo-
Wizard tool msConvert, and the exported MGF files were searched using Mascotversion
2.3.02 in this project against the selected database. At least one unique peptide was necessary
for the identified protein. The databases used were: NCBInr, SwissProt, UniProt. An auto-
mated software called IQuant was used for quantitatively analyzing the labeled peptides with
isobaric tags. It integrates Mascot Percolator, a well-performing machine learning method for
rescoring database search results, to provide reliable significance measures. To assess the confi-
dence of peptides, the PSMs were pre-filtered at a PSM-level FDR of 1%. Then based on the
"simple principle" (the parsimony principle), identified peptide sequences are assembled into a
set of confident proteins. To control the rate of false-positive identifications at the protein
level, an FDR threshold of 1% was used, which is based on Picked protein FDR strategy, will
also be estimated after protein inference (protein-level FDR < = 0.01). The protein quantifica-
tion process includes the following steps: protein identification, tag impurity correction, data
normalization, missing value imputation, protein ratio calculation, statistical analysis, results
presentation. Protein identification was supported by all peptide matches with 95% confi-
dence. Comparisons were made between genotypes and proteins were considered to be differ-
entially that met the criteria of p< 0.05 and absolute fold change > 1.2.
StringDB analysis. Differentially expressed proteins were analyzed using STRING analy-
sis [40]. We filter excluded any proteins lacking interactions and used the Markov cluster algo-
rithm (MCL) with an inflation parameter of three to identify clusters of related proteins based
on their interaction network. Simultaneously, we used functional enrichment to identify bio-
logical processes, cellular components, and pathways that were over-represented in our pro-
tein list using a false discovery rate of less than 5%.
Supporting information
S1 Video. Performance on the accelerating rotoarod is decreased in adult rats homozygous
for CHIP-T246M. Three rats with either the M246/M246 (left) or T246/T246 (right) geno-
types were placed on the non-moving rod. Once the rod starts to rotate, M246/M246 mice fall
off within 15 s.
(MP4)
S2 Video. The effect of CHIP-T246M on hind limb clasping. Mice with the M246/M246
(left, blue glove) or T246/T246 (right, white glove) genotype were tested for hind limb clasping.
Increased clasping was observed in M246/M246 mice and further increased with age, relative
to control mice.
(MOV)
S3 Video. The effect of CHIP gene disruption on hind limb clasping. Mice that lack CHIP
expression (left, blue glove) or a wild-type litter mate (right, white glove), were tested for hind
limb clasping. Increased clasping was observed in CHIP−/− mice and further increased with
age, relative to control mice.
(MOV)
S1 Table. Proteomics analysis of differentially expressed cerebellar proteins identified in
the CHIP-T246M rat model. The protein name is provided along with the values of each pro-
tein from biological replicates of M246/M246 cerebellums (M1, M2, and M3) relative to the
mean values of three T246/T246 biological replicates. The mean of all three replicates, the stan-
dard deviation (SD), and the p value comparing M246/M246 vs. T246/T246 conditions are
indicated. Additional annotations of each protein, including database ID, the mass, and
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decryption are provided.
(XLSX)
S2 Table. Cluster analysis of interacting proteins. Each cluster was color coded as found in
Fig 10B. The number of proteins in each cluster, the protein name, ID, and description is pro-
vided.
(XLSX)
S1 Fig. Reaction time in the acoustic startle response. The reaction time of the startle follow-
ing the acoustic stimulus (AS) in CHIP null mice (−/−, N = 6) and wild-type mice (+/+,
N = 10) represented by the mean ± SEM: 2-way ANOVA, p< 0.001 on genotype (main effect),
 corresponds to p< 0.05 comparing genotypes via Sidak’s post hoc test.
(TIF)
S2 Fig. Unsupervised cluster analysis of differentially expressed proteins due to
CHIP-T246M. Proteins were clustered using Ward linkage analysis. Each column is the mean
of a biological replicate of an M246/M246 cerebellum relative to T246/T246 control cere-
bellums. The two primary clusters represent proteins that are either increased (left) or
decreased (right) in M246/M246 cerebellums as indicated by the color bar.
(TIF)
S3 Fig. Immunoblots of differentially expressed proteins due to CHIP-T246M with age.
Representative immunoblots of the indicated proteins from either cerebellum or brain extracts
isolated from rats with the indicated genotypes and age.
(TIF)
S4 Fig. Generation the corresponding CHIP-T246M mutation at the endogenous locus of
Stub1 in Rattus norvegicus using CRISPR/Cas9. (A) Schematic of targeting vector used for
in vivo genome editing, targeting the Cas9 nuclease to exon 6. (B) Map of Cas9 vector. (C)
Map of Stub1 T247M targeting vector (rodents have an additional coding exon relative to
humans). (D) Sanger sequencing confirmation of the T246M mutation, changing the coding
exon from ACA (threonine) to ATG (methionine).
(TIF)
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20. Hayer SN, Deconinck T, Bender B, Smets K, Züchner S, Reich S, et al. STUB1/CHIP mutations cause
Gordon Holmes syndrome as part of a widespread multisystemic neurodegeneration: evidence from
four novel mutations. Orphanet J Rare Dis. 2017; 12: 31. https://doi.org/10.1186/s13023-017-0580-x
PMID: 28193273
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